Citations

Mayo Clinic

Showing 10 of 108522 citations.

Digital Education on Hospital Nutrition Diets: What Do Patients Want to Know?
Gutta, Neha , Patel, Dharti , Jamal, Aleena, Qureshi, Fawad , Qureshi, Fawad , Singh, Som Prabh

Nutrients | September 30, 2024 | Volume: 16 | Issue: 19 | Pages: 3314

10.3390/nu16193314 | PMID 39408281 Get It

Introduction: Therapeutic nutrition plays an imperative role during a patient’s hospital course. There is a tremendous body of literature that emphasizes the systematic delivery of information regarding hospital nutrition diets. A major component of delivering healthcare information is the principle of providing quality healthcare information, but this has not yet been investigated on hospital nutrition diets. This study aimed to evaluate the comprehension and readability of patient education materials regarding therapeutic hospital diets. Methodology: The methodology employed the use of publicly available questions regarding hospital nutrition diets and categorized them per Rothwell’s Classification of Questions. Additionally, the questions were extracted online and have an associated digital article linked to the question. These articles underwent analysis for readability scores. Results: This study’s findings reveal that most hospital diets do not meet the recommended grade-reading levels. Conclusions: This underscores the need for healthcare providers to enhance patient education regarding hospital diets. The prevalence of “Fact” questions showcases the importance of clearly explaining diets and dietary restrictions to patients.
Fueling the Firefighter and Tactical Athlete with Creatine: A Narrative Review of a Key Nutrient for Public Safety
Gonzalez, Drew E. , Forbes, Scott C. , Zapp, Annette , Jagim, Andrew R. , Luedke, Joel, Root, Alexandria, Gil, Adriana , Johnson, Sarah E. , Coles, Macilynn E., Brager, Allison J. , Sowinski, Ryan , Candow, Darren G. , Kreider, Richard B. , Jagim, Andrew R , Sowinski, Ryan J , Kreider, Richard B , Forbes, Scott C , Dickerson, Broderick L.

Nutrients | September 30, 2024 | Volume: 16 | Issue: 19 | Pages: 3285

10.3390/nu16193285 | PMID 39408252 Get It

Background/Objectives: Firefighters, tactical police officers, and warriors often engage in periodic, intermittent, high-intensity physical work in austere environmental conditions and have a heightened risk of premature mortality. In addition, tough decision-making challenges, routine sleep deprivation, and trauma exacerbate this risk. Therefore, identifying strategies to bolster these personnel’s health and occupational performance is critical. Creatine monohydrate (CrM) supplementation may offer several benefits to firefighters and tactical athletes (e.g., police, security, and soldiers) due to its efficacy regarding physical performance, muscle, cardiovascular health, mental health, and cognitive performance. Methods: We conducted a narrative review of the literature with a focus on the benefits and application of creatine monohydrate among firefighters. Results: Recent evidence demonstrates that CrM can improve anaerobic exercise capacity and muscular fitness performance outcomes and aid in thermoregulation, decision-making, sleep, recovery from traumatic brain injuries (TBIs), and mental health. Emerging evidence also suggests that CrM may confer an antioxidant/anti-inflammatory effect, which may be particularly important for firefighters and those performing tactical occupations exposed to oxidative and physiological stress, which can elicit systemic inflammation and increase the risk of chronic diseases. Conclusions: This narrative review highlights the potential applications of CrM for related tactical occupations, with a particular focus on firefighters, and calls for further research into these populations.
Endovascular thrombectomy for severe cerebral venous thrombosis: A comprehensive meta-analysis assessing safety and efficacy
Ghozy, Sherief , Tolba, Hatem , Abdelghaffar, Mariam , Kobeissi, Hassan , Ghaith, Hazem S. , Abbas, Alzhraa Salah , Kadirvel, Ramanathan , Brinjikji, Waleed , Kallmes, David F. , Kobeissi, Hassan , Abbas, Alzhraa S, Kadirvel, Ram , Kallmes, David F , Ghozy, Sherief , Orscelik, Atakan , Abbas, Alzhraa Salah

Interventional Neuroradiology | September 30, 2024 | Volume: 32 | Issue: 4 | Pages: 1765-1774

10.1177/15910199241285071 | PMID 39344306 Get It

Background Cerebral sinus venous thrombosis (CSVT) has traditionally been treated medically with systemic anticoagulation. Recent advances in endovascular therapy (EVT) may represent an alternative treatment to medical therapy for CSVT. We conducted a systematic review and meta-analysis to evaluate the use of EVT for CSVT. Methods We conducted a systematic literature review using PubMed, Embase, Scopus, and Web of Science. We included studies that reported outcomes following EVT for CSVT. The primary outcome of interest was rate of modified Rankin Scale (mRS) 0–2. Secondary outcomes of interest were rates of complete, partial, and failed recanalization, mortality, and new or expansion of hematoma. We calculated pooled rates (%) and their corresponding 95% confidence intervals (CIs). Results Thirty-eight studies with 682 patients were included. Rate of mRS 0–2 was 82.6% (95% CI, 75.3%–88.0%). Rate of complete recanalization was 60.9% (95% CI, 49.1%–71.5%), rate of partial recanalization was 34.2% (95% CI, 24.1%–45.9%), and rate of failed recanalization was 5.4% (95% CI, 3.1%–9.2%). Rate of mortality was 6.7% (95% CI, 4.1%–10.8%), and rate of new hematoma or expansion of hematoma was 5.1% (2.9%–8.8%). Conclusions In this systematic review and meta-analysis, EVT for CSVT was associated with favorable rates of mRS 0–2 and recanalization. Furthermore, EVT was associated with a promising safety profile. Future prospective, comparative studies are warranted to assess EVT for CSVT.
Opioid Prescribing for Acute Pain Management in Children and Adolescents in Outpatient Settings: Clinical Practice Guideline
Hadland, Scott E. , Agarwal, Rita , Raman, Sudha R. , Bryl, Amy W., Michel, Jeremy J. , Renny, Madeline H. , Larson-Steckler, Beth, Wexelblatt, Scott L. , Wilder, Robert T., Flinn, Susan K., Humphrey, Lisa, Walker-Harding, Leslie, Webb, Michael, Emmer, Suzanne, Okechukwu, Kymika, Nunnery, Cordarrell, Smith, Michael John , Kelley‐Quon, Lorraine I. , Raval, Mehul V. , Humphrey, Lisa, Walker-Harding, Leslie, Webb, Michael, Emmer, Suzanne, Okechukwu, Kymika, Nunnery, Cordarrell

Pediatrics | September 30, 2024 | Volume: 154 | Issue: 5 | Pages: No page available

10.1542/peds.2024-068752 | PMID 39344439 Get It

This is the first clinical practice guideline (CPG) from the American Academy of Pediatrics outlining evidence-based approaches to safely prescribing opioids for acute pain in outpatient settings. The central goal is to aid clinicians in understanding when opioids may be indicated to treat acute pain in children and adolescents and how to minimize risks (including opioid use disorder, poisoning, and overdose). The document also seeks to alleviate disparate pain treatment of Black, Hispanic, and American Indian/Alaska Native children and adolescents, who receive pain management that is less adequate and less timely than that provided to white individuals. There may also be disparities in pain treatment based on language, socioeconomic status, geographic location, and other factors, which are discussed. The document recommends that clinicians treat acute pain using a multimodal approach that includes the appropriate use of nonpharmacologic therapies, nonopioid medications, and, when needed, opioid medications. Opioids should not be prescribed as monotherapy for children or adolescents who have acute pain. When using opioids for acute pain management, clinicians should prescribe immediate-release opioid formulations, start with the lowest age- and weight-appropriate doses, and provide an initial supply of 5 or fewer days, unless the pain is related to trauma or surgery with expected duration of pain longer than 5 days. Clinicians should not prescribe codeine or tramadol for patients younger than 12 years; adolescents 12 to 18 years of age who have obesity, obstructive sleep apnea, or severe lung disease; to treat postsurgical pain after tonsillectomy or adenoidectomy in patients younger than 18 years; or for any breastfeeding patient. The CPG recommends providing opioids when appropriate for treating acutely worsened pain in children and adolescents who have a history of chronic pain; clinicians should partner with other opioid-prescribing clinicians involved in the patient’s care and/or a specialist in chronic pain or palliative care to determine an appropriate treatment plan. Caution should be used when treating acute pain in those who are taking sedating medications. The CPG describes potential harms of discontinuing or rapidly tapering opioids in individuals who have been on stable, long-term opioids to treat chronic pain. The guideline also recommends providing naloxone and information on naloxone, safe storage and disposal of opioids, and direct observation of medication administration. Clinicians are encouraged to help caregivers develop a plan for safe disposal. The CPG contains 12 key action statements based on evidence from randomized controlled trials, high-quality observational studies, and, when studies are lacking or could not feasibly or ethically be conducted, from expert opinion. Each key action statement includes a level of evidence, the benefit-harm relationship, and the strength of recommendation.
Symptomatic Pneumorrhachis from Bronchial-Subarachnoid Fistula
Lipinski, Alexander W. , Smith, Mathew V. , Wannamaker, Eric J., Timpone, Vincent M. , Smith, Mathew

Diagnostics | September 30, 2024 | Volume: 14 | Issue: 19 | Pages: 2170

10.3390/diagnostics14192170 | PMID 39410574 Get It

Bronchial-subarachnoid fistulas are rare occurrences, which are not well defined in the literature. This uncommon clinical phenomenon may result in symptomatic pneumorrhachis and presents unique clinical challenges. This report details a case of a 53-year-old female whose treatment for recurrent chondrosarcoma of the thoracic spine included multiple surgeries and radiotherapy. Two weeks after her most recent debulking surgery, she experienced a rapid onset of unusual symptoms, including headache, back and neck spasms, bladder incontinence, and confusion. The source of her symptoms was found to be secondary to pneumorrhachis from a pre-existing bronchial-pleural fistula that had fistulized to the subarachnoid space discovered on computed tomography (CT) and confirmed intraoperatively. The patient was treated successfully with high-flow oxygen therapy and bed rest, followed by surgical correction of both a pleural air leak and a dural defect with muscular flaps. The patient was discharged home in stable condition and remained clinically free of recurrent bronchial-subarachnoid fistula six months after surgical repair. This case contributes to the existing literature by providing detailed clinical insights into the diagnosis and successful management of a bronchial-subarachnoid fistula leading to pneumorrhachis, thereby highlighting the importance of early recognition and intervention and underscoring the need for further research in this area.
The Role of CENPK Splice Variant in Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer
Huang, Minhong , Gao, Huanyao , Kim, Wootae , John, August , Weinshilboum, Richard M. , Wang, Liewei , Xie, Fang , Gao, Huanyao , Kim, Wootae , John, August , Qin, Sisi , Xie, Fang , Yin, Ping , Weinshilboum, Richard M.

Cells | September 30, 2024 | Volume: 13 | Issue: 19 | Pages: 1622

10.3390/cells13191622 | PMID 39404386 Get It

Most patients with metastatic prostate cancer eventually develop resistance to primary androgen deprivation therapy. To identify predictive biomarker for Abiraterone acetate/prednisone resistance, we screened alternative splice variants between responders and non-responders from the PROMOTE clinical study and pinned down the most significant variant, CENPK–delta8. Through preclinical patient-derived mouse xenograft (PDX) and 3D organoids obtained from responders and non-responders, as well as in vitro models, aberrant CENPK–delta8 expression was determined to link to drug resistance via enhanced migration and proliferation. The FLNA and FLOT1 were observed to specifically bind to CENK–delta8 rather than wild-type CENPK, underscoring the role of CENPK–delta8 in cytoskeleton organization and cell migration. Our study, leveraging data from the PROMOTE study, TCGA, and TCGA SpliceReq databases, highlights the important function of alternative splice variants in drug response and their potential to be prognostic biomarkers for improving individual therapeutic outcomes in precision medicine.
Novel risk score for predicting acute cardiovascular and cerebrovascular events after chest radiotherapy in patients with breast or lung cancer
Rmilah, Anan Abu , Adham, Alkurashi, I, Haq, Nandan, Anevakar, Jouni, Hayan, Hirashi, Satomi, Owen, Dawn, Deswal, Anita , Chao, Tzu Cheng , Herrmann, Joerg , AbuRmilah, Anan , Abu Rmilah, Anan , Ikram-Ul, Haq, Alzu'bi, Hossam, Deswal, Anita M , Browne, Jacinta , Herrmann, Joerg , Abu Rmilah, Anan A , Alzu’bi, Hossam , Lin, Steven H. , Abe, Jun-Ichi , Browne, Jacinta E. , Leiner, Tim , Laack, Nadia N.

European Journal of Preventive Cardiology | September 29, 2024 | Volume: 33 | Issue: 4 | Pages: 513-525

10.1093/eurjpc/zwae323 | PMID 39453776 Get It

Abstract Aims Radiation therapy (RT) is an integral component of cancer therapy but associated with adverse events. Our goal was to establish risk prediction models for major adverse cardiovascular and cerebrovascular events (MACCE) after chest RT. Methods and results A retrospective study of lung/breast cancer patients who had chest RT with planning CT at Mayo Clinic between 01/2010 and 01/2014. Predictive models were developed based on weighted independent predictors using a derivation (406 lung and 711 breast cancer) and validation cohort (179 lung and 234 breast cancer). Patient characteristics, pre-RT CT for coronary artery calcification (CAC), and post-RT MACCE data were reviewed. Post-RT MACCE occurred in 6.1 and 5.6% in the derivation and validation cohort over a mean follow-up of 42 ± 13 months. Post-therapy model (C2AD2) included CAC (two points), MACCE history (two points), age ≥74 (three points), DM (two points), and mean heart radiation dose ≥ 850 mGy (two points), and pre-therapy model (C2AD) included post-therapy model parameters minus mean heart radiation dose. Both models stratified patients into three risk groups: low (0–2), intermediate (3–5), and high (≥6). Post-RT MACCE across these groups were 2.7, 8.9, and 19.8% in the derivation, and 3.9, 6.6, and 16.4% in the validation cohort for post-therapy model (C2AD2) and 2.8, 9.2, and 20.4% in the derivation and 3.7, 9.2, and 13.2% in the validation cohort for pre-therapy model. Both models showed statistically significant graded survival outcome. Conclusion Post-therapy (C2AD2) and pre-therapy (C2AD) models are simple, easy to use and effective tools to stratify breast and lung cancer patients undergoing chest radiation for post-RT MACCE.
Harnessing the Power of Generative Artificial Intelligence in Pathology Education: Opportunities, Challenges, and Future Directions
Cecchini, Matthew J. , Borowitz, M, Glassy, Eric F., Gullapalli, Rama R. , Hassell, Lewis , Jackups, Ronald , McNeal, Jeffrey L., Anderson, Scott R. , Hart, Steven N. , Homer, Robert , McNeal, Jeffrey L.

Archives of Pathology & Laboratory Medicine | September 29, 2024 | Volume: 149 | Issue: 2 | Pages: 142-151

10.5858/arpa.2024-0187-ra | PMID 39343982 Get It

Context.— Generative artificial intelligence (AI) technologies are rapidly transforming numerous fields, including pathology, and hold significant potential to revolutionize educational approaches. Objective.— To explore the application of generative AI, particularly large language models and multimodal tools, for enhancing pathology education. We describe their potential to create personalized learning experiences, streamline content development, expand access to educational resources, and support both learners and educators throughout the training and practice continuum. Data Sources.— We draw on insights from existing literature on AI in education and the collective expertise of the coauthors within this rapidly evolving field. Case studies highlight practical applications of large language models, demonstrating both the potential benefits and unique challenges associated with implementing these technologies in pathology education. Conclusions.— Generative AI presents a powerful tool kit for enriching pathology education, offering opportunities for greater engagement, accessibility, and personalization. Careful consideration of ethical implications, potential risks, and appropriate mitigation strategies is essential for the responsible and effective integration of these technologies. Future success lies in fostering collaborative development between AI experts and medical educators, prioritizing ongoing human oversight and transparency to ensure that generative AI augments, rather than supplants, the vital role of educators in pathology training and practice.
Breastfeeding experiences among young breast cancer survivors: A survey study
Sella, Tal , Sorouri, Kimia , Rosenberg, Shoshana M. , Loucks, Maggie, Kirkner, Gregory J. , Snow, Craig , Ruddy, Kathryn J. , Gelber, Shari , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Kirkner, Gregory , Peppercorn, Jeffrey M , Schapira, Lidia , Warner, Ellen , Partridge, Ann H , Snow, Craig , Tamimi, Rulla M. , Borges, Virginia F. , Warner, Ellen , Partridge, Ann H.

Cancer | September 29, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35585 | PMID 39342485 Get It

ABSTRACTBackgroundFollowing breast cancer (BC), many young women are interested in future childbearing and some may wish to breastfeed. However, limited information is available regarding their lactation experiences.MethodsParticipants in the Young Women's Breast Cancer Study, a multicenter, prospective cohort study of women ≤40 years diagnosed with stage 0–III BC between 2006–2016 and who reported one or more live births following diagnosis, were surveyed about pregnancy and breastfeeding after BC treatment, including reasons for attempting and stopping breastfeeding, satisfaction, and supports.ResultsOf 143 eligible women sent a survey, 115 responded and 94 were included in the analytic cohort. Breastfeeding was attempted by 55% of women (52 of 94). Among those who had not attempted, 93% noted prior bilateral mastectomies (39 of 42). Among those who attempted breastfeeding, 69% had undergone lumpectomy and radiotherapy (36 of 52), 83% of whom reported no milk production from their treated breast (30 of 36). Most (65%, 34 of 52) were at least somewhat satisfied with their ability to breastfeed. Reasons for stopping breastfeeding included: having completed the planned duration (36%, 19 of 52); to start/resume endocrine therapy (21%, 11 of 52); and to resume breast imaging (8%, 4 of 52). Approximately half (27 of 55) of women who had not undergone bilateral mastectomies recalled receiving specific information about breastfeeding after BC, mostly from the oncology team (59%, 16 of 27), online resources (48%, 13 of 27), or a lactation consultant (44%, 12 of 27).ConclusionMost young BC survivors who attempted to breastfeed were able to and were satisfied with the experience, despite challenges. Specific resources to support BC survivors who wish to breastfeed are needed.
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses
Seligson, Nathan D. , Chen, James L. , Goodrich, Austin C, Tine, Brian A. Van , Campbell, Jordan D., Richards, Allison L. , Milhem, Mohammed , Streicher, Howard , Tap, William D. , Van Tine, Brian A , D'Angelo, Sandra P , Milhem, Mohammed M , Antonescu, Cristina R. , Liebner, David A. , Schwartz, Gary K. , George, Suzanne

Journal for ImmunoTherapy of Cancer | September 29, 2024 | Volume: 12 | Issue: 9 | Pages: e009472

10.1136/jitc-2024-009472 | PMID 39343511 Get It

Background In this open-label, randomized, non-comparative, multicenter phase II study (Alliance A091401) we report on three expansion cohorts treated with nivolumab (N) with and without ipilimumab (N+I) and provide a multi-omic correlative analysis of actionable biomarkers. Methods Patients were randomized (non-comparative) to receive either N or N+I. The primary endpoint was a 6-month confirmed response rate (CRR) defined by Response Evaluation Criteria in Solid Tumors version 1.1. Secondary endpoints included treatment-related adverse events (TRAEs), progression-free survival, and overall survival. Multi-omic correlative analyses were conducted using samples from both the primary and expansion cohorts. Results A total of 66 patients were evaluated for the primary endpoint with disease including gastrointestinal stromal tumor (GIST, n=18), undifferentiated pleomorphic sarcoma (UPS, n=24), and dedifferentiated liposarcoma (DDLPS, n=24). Neither N nor N+I achieved a complete or partial response in the GIST expansion cohort. In DDLPS and UPS, the primary response endpoint of CRR was met with N+I (both 16.6%, 2/12) but not with N alone (both 8.3%, 1/12). In the GIST cohort, TRAE was higher with N+I treatment, halting enrollment as required per protocol. In a correlative analysis of patients for the expansion cohort and the original cohort (n=86), traditional biomarkers of immunotherapy response were not correlated with response in any histological subtype. Markers of genomic instability including the presence of gene fusions and increased subclonal mutations correlated with improved clinical outcomes. Conclusions This expansion cohort reaffirms the outcomes of A091401. There remains a pressing need to determine the role of and predictive biomarkers for immunotherapy in sarcoma. Trial registration number NCT02500797.